Integra LifeSciences (NASDAQ:IART) Releases FY 2026 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY 2026 earnings guidance on Friday morning. The company provided EPS guidance of 2.300-2.400 for the period, compared to the consensus earnings per share estimate of 2.460. The company issued revenue guidance of $1.6 billion-$1.7 billion. Integra LifeSciences also updated its Q3 2026 guidance to 0.550-0.590 EPS.

Wall Street Analyst Weigh In

IART has been the subject of a number of research reports. UBS Group started coverage on shares of Integra LifeSciences in a research report on Tuesday, July 28th. They set a “neutral” rating and a $19.00 price target for the company. Citigroup reissued a “neutral” rating and issued a $19.00 price target (up from $16.00) on shares of Integra LifeSciences in a report on Wednesday, July 8th. Weiss Ratings upgraded Integra LifeSciences from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 14th. Wall Street Zen downgraded Integra LifeSciences from a “strong-buy” rating to a “buy” rating in a research report on Saturday, July 18th. Finally, BMO Capital Markets started coverage on shares of Integra LifeSciences in a research note on Wednesday, July 8th. They issued a “market perform” rating and a $19.00 target price on the stock. One investment analyst has rated the stock with a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Integra LifeSciences currently has an average rating of “Reduce” and a consensus target price of $18.86.

Integra LifeSciences Price Performance

Integra LifeSciences stock opened at $16.09 on Friday. The stock’s 50 day moving average is $16.83 and its 200 day moving average is $15.17. The firm has a market cap of $1.25 billion, a P/E ratio of -178.76, a P/E/G ratio of 0.84 and a beta of 1.21. The company has a debt-to-equity ratio of 1.75, a current ratio of 3.60 and a quick ratio of 2.11. Integra LifeSciences has a one year low of $8.70 and a one year high of $20.49.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Wednesday, July 29th. The life sciences company reported $0.56 EPS for the quarter, beating analysts’ consensus estimates of $0.48 by $0.08. Integra LifeSciences had a positive return on equity of 18.30% and a negative net margin of 0.44%.The business had revenue of $418.76 million during the quarter, compared to analyst estimates of $417.54 million. Integra LifeSciences has set its Q3 2026 guidance at 0.530-0.610 EPS and its FY 2026 guidance at 2.400-2.500 EPS. As a group, research analysts expect that Integra LifeSciences will post 2.46 EPS for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation (NASDAQ:IART) is a global medical technology company that develops and manufactures products used in neurosurgery, reconstructive surgery, and orthopedic procedures. Its offerings are designed to help physicians treat neurological conditions, traumatic injuries, complex wounds, and other surgical needs.

The company’s products include dural repair and regeneration materials, cerebrospinal fluid management systems, surgical instruments, nerve and tendon repair products, and tissue-engineered solutions for wound care and reconstructive surgery.